ID   UM-UC-5
AC   CVCL_2750
SY   UMUC5; University of Michigan-Urothelial Carcinoma-5
DR   BTO; BTO:0004993
DR   cancercelllines; CVCL_2750
DR   Cell_Model_Passport; SIDM01909
DR   Cosmic; 1082648
DR   Cosmic; 1938702
DR   Cosmic; 2037969
DR   Cosmic; 2700983
DR   DepMap; ACH-001411
DR   ECACC; 08090502
DR   GEO; GSM1567863
DR   GEO; GSM1574558
DR   Wikidata; Q54990992
RX   PubMed=3761468;
RX   PubMed=24018021;
RX   PubMed=25997541;
RX   PubMed=29732388;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Doubling time: 19 hours (PubMed=3761468).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp53Ter (c.159G>A); ClinVar=VCV000420659; Zygosity=Unspecified (DepMap=ACH-001411).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): DepMap=ACH-001411; ECACC=08090502
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8,12
ST   D16S539: 11,13
ST   D18S51: 13,16
ST   D21S11: 32.2
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 10,12
ST   D8S1179: 12,13
ST   FGA: 20
ST   Penta D: 9
ST   Penta E: 15,17
ST   TH01: 7,9
ST   TPOX: 9,11
ST   vWA: 16,18
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
//
RX   PubMed=3761468; DOI=10.1016/S0022-5347(17)45139-1;
RA   Grossman H.B., Wedemeyer G., Ren L.-Q., Wilson G.N., Cox B.;
RT   "Improved growth of human urothelial carcinoma cell cultures.";
RL   J. Urol. 136:953-959(1986).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//